Compare H2O America (HTO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Merck & Co., Inc. — how do they compare? H2O America trades at $58.48 (market cap $2.43B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 144.6× H2O America's market cap, and H2O America pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Merck & Co., Inc. for 98 Days on average.
| HTO | MRK | |
|---|---|---|
Market Cap | $2.43B | $351.28B |
Volume | 593,883 | 7,969,665 |
Sector | Utilities | Health |
52-Week High | $65.43 | $156.43 |
52-Week Low | $44.44 | $82.49 |
Typical Hold Time | 40 Days | 98 Days |
Enterprise Value | $4.22B | $398.04B |
Dividend Yield | 3.03% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.07, up 0.16% with a bearish technical signal despite bullish oscillators. The company shows solid fundamentals with 12.91% net income margin and recent earnings beats in Q1 and Q2 2026. Recent acquisitions in Texas signal growth ambitions, though cash flow trends show heavy investing activity. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target.
The stock offers potential upside to analyst targets but faces execution risks from recent acquisitions and dilution concerns. Strong institutional interest from BlackRock and others supports the growth story, though technical weakness and high investing cash outflows warrant monitoring. The Dividend King status provides income stability amid expansion efforts.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
